PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved biotherapeutics for the treatment of serious rare diseases, with an initial focus on cardiopulmonary indications. We are leveraging our proprietary elastin-like polypeptide technology to advance a pipeline of drug candidates with the potential for less frequent dosing and better patient compliance.
Our proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects, which can lead to less frequent dosing and better patient compliance.